November 2023
1. TAN X, Wang Y, Wu Z, Zhou Q, et al
   The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy.
   Eur J Cancer. 2023;194:113360.
   

   >> Share

   
   January 2023
2. ANTONELLI L, Ardizzone D, Ravi P, Bagrodia A, et al
   Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospe
   Eur J Cancer. 2023;182:144-154.
   

   >> Share

   
   September 2022
3. WANG Y, Lian B, Si L, Mao L, et al
   Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III.
   Eur J Cancer. 2022;175:196-203.
   

   >> Share

   
   May 2022
4. MIFSUD W, Furtwangler R, Vokuhl C, D'Hooghe E, et al
   Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies.
   Eur J Cancer. 2022;166:1-7.
   

   >> Share

   
   March 2022
5. ALIFRANGIS C, Sharma A, Chowdhury S, Duncan S, et al
   Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients.
   Eur J Cancer. 2022;164:105-113.
   

   >> Share

   
   October 2021
6. MALUF FC, Schutz FA, Cronemberger EH, Luz MA, et al
   A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
   Eur J Cancer. 2021;158:63-71.
   

   >> Share

   
   
7. VOLDERS ELD, Gietema JA, van Beek AP, Emous M, et al
   Bariatric surgery in a testicular cancer survivor: Restoring both metabolic and testosterone status.
   Eur J Cancer. 2021;158:12-14.
   

   >> Share

   
   September 2021
8. HOVEN E, Fagerkvist K, Jahnukainen K, Ljungman L, et al
   Sexual dysfunction in young adult survivors of childhood cancer - A population-based study.
   Eur J Cancer. 2021;154:147-156.
   

   >> Share

   
   August 2021
9. HIESTER A, Fingerhut A, Niegisch G, Siener R, et al
   Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a
   Eur J Cancer. 2021;155:64-72.
   

   >> Share

   
   July 2021
10. SALZMANN M, Tosev G, Heck M, Schadendorf D, et al
    Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study.
    Eur J Cancer. 2021;152:41-48.
    

    >> Share

    
    February 2021
11. ANDERSON RA, Clatot F, Demeestere I, Lambertini M, et al
    Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments.
    Eur J Cancer. 2021;144:310-316.
    

    >> Share

    
    March 2020
12. GILBERT A, Drinkwater K, McParland L, Adams R, et al
    UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
    Eur J Cancer. 2020;128:7-16.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share